Registered title, quoted from ClinicalTrials.gov
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
An open trial on lung cancer and breast cancer, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT03392233, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 85 years; sex: all
Registered eligibility fields
The primary lesion was confirmed by pathology or cytology;
Inclusion criterion 2
The metastatic lesions were diagnosed by imaging(CT,MRI,PET-CT,ECT),or the lesions were confirmed by biopsy;
Inclusion criterion 3
Leukocytes ≥ 3.0 x109/ L;
Inclusion criterion 7
Absolute neutrophil count (ANC) ≥ 1.5 x109/ L;
Inclusion criterion 8
Platelet count ≥ 100 x109/ L;
Inclusion criterion 9
Hemoglobin (Hb) ≥ 9g/ dL;
Inclusion criterion 10
Total bilirubin ≤1.5 x the upper limit of normal (ULN);
Inclusion criterion 11
Alanine aminotransferase (ALT) ≤ 3 x ULN;
Inclusion criterion 12
Aspartate aminotransferase (AST) ≤ 3 x ULN;
Inclusion criterion 13
Serum creatinine ≤ 1.5 x the ULN;
Inclusion criterion 14
The enhanced MRI scan of involved vertebral bodies was required in the 2 weeks before radiotherapy;
Inclusion criterion 6
Pregnant and Nursing women;
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03392233, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- WHO scores 0-2;
- The primary lesion was confirmed by pathology or cytology;
- The metastatic lesions were diagnosed by imaging(CT,MRI,PET-CT,ECT),or the lesions were confirmed by biopsy;
- The metastatic lesion was limited in 3 consecutive vertebral bodies;
- The baseline pain score was ≥5(NRPS) and the use of analgesic drugs was recorded;
- The enhanced MRI scan of involved vertebral bodies was required in the 2 weeks before radiotherapy;
Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
- Leukocytes ≥ 3.0 x109/ L;
- Absolute neutrophil count (ANC) ≥ 1.5 x109/ L;
- Platelet count ≥ 100 x109/ L;
- Hemoglobin (Hb) ≥ 9g/ dL;
- Total bilirubin ≤1.5 x the upper limit of normal (ULN);
- Alanine aminotransferase (ALT) ≤ 3 x ULN;
- Aspartate aminotransferase (AST) ≤ 3 x ULN;
- Serum creatinine ≤ 1.5 x the ULN;
- Signed informed consent;
Exclusion Criteria:
- There were significant changes in the shape of the vertebral body (the height of the vertebral body was compressed≥ 50%) or the vertebral body was unchanged but the volume of the dissolving bone was≥ 50% and could lead to serious bone adverse events;
- There were >3 consecutive vertebral bodies involved;
- Spinal cord compression has occurred;
- The gap between tumor and spinal cord was less than 3mm;
- The metastatic area previously received radiation;
- Pregnant and Nursing women;
- Uncontrolled co-morbid illnesses;
9.refused to signed informed consent;
Quoted from ClinicalTrials.gov, NCT03392233, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT03392233, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.